Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Analysis
  5. Spotlight

Spotlight

Evaluate

May 18, 2023

Spotlight – Few signs of gout pipeline flaring up

Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.

Thumbnail
May 09, 2023

Gene editing: overhyped or unstoppable tide?

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

Article image
Vantage logo
May 05, 2023

Spotlight – Travere trips up but others are following in rare kidney disease

Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.

Article image
Vantage logo
April 24, 2023

Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation

The group is fast developing its new atrial fibrillation devices. But will it be fast enough?

Article image
Vantage logo
April 03, 2023

Spotlight – following Humira in hidradenitis suppurativa

Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.

Article image
Vantage logo
March 24, 2023

Spotlight – Vertex flexes its dealmaking muscle

The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.

Article image
Vantage logo
March 08, 2023

Spotlight – Seeking target selectivity in achondroplasia

As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?

Article image
Vantage logo
March 03, 2023

Spotlight – What's next in Nash

The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.

Article image
Vantage logo
February 24, 2023

Spotlight – Cystic fibrosis developers take a deep breath

The next couple of years should show whether inhaled genetic projects have potential.

Article image
Vantage logo
February 22, 2023

US deal watchdog's bark could be worse than its bite

Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?  

Article image
Vantage logo
February 15, 2023

Spotlight – still plenty of hopefuls in lung fibrosis

Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up